EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity

Olufemi Aoko iD, Tobias Maharaj iD, Fiona Boland iD, Danny Cheriyan iD, John Ryan iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17805 ↗

At a glance

Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, 2024. Written by Olufemi Aoko and 4 co-authors. Institution: Hepatology Department, Beaumont Hospital, Dublin, Ireland. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Gastric Balloon, Bariatric Surgery. Cited 16 times so far (Crossref); 65 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Beaumont Hospital Dublin, Charitable Infirmary Charitable Trust - Kieran Taaffe Bursary, Royal College of Surgeons in Ireland.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.

Aim

To evaluate the effect of IGB as a treatment option in NAFLD.

Methods

We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.

Results

We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.

Conclusion

Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseGastric BalloonBariatric SurgeryAdultHumansObesity

Author keywords

Intragastric balloonbariatric endoscopyendoscopic bariatric therapiesinsulin resistancenon-alcoholic fatty liver diseaseobesity

Authors and institutions

  • Hepatology Department, Beaumont Hospital, Dublin, Ireland.
  • Gastroenterology Department, Beaumont Hospital, Dublin, Ireland.
  • Royal College of Surgeons Ireland, Dublin, Ireland.

ORCID profiles: Olufemi Aoko, Tobias Maharaj, Fiona Boland, Danny Cheriyan, John Ryan

Funding

  • Beaumont Hospital Dublin
  • Charitable Infirmary Charitable Trust - Kieran Taaffe Bursary
  • Royal College of Surgeons in Ireland

Cite

APA

Aoko, O., Maharaj, T., Boland, F., Cheriyan, D., & Ryan, J. (2024). Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17805

Vancouver

Aoko O, Maharaj T, Boland F, Cheriyan D, Ryan J. Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17805

BibTeX
@article{Aoko2024,
  author = {Aoko, Olufemi and Maharaj, Tobias and Boland, Fiona and Cheriyan, Danny and Ryan, John},
  title = {Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17805}
}
Start for free →